Tevogen.ai Secures Patent for AI Immunological Peptide Prediction Technology
Tevogen Bio Holdings (Nasdaq: TVGN) has secured a patent for its machine learning-driven system designed to predict immunologically active...
eurneffy® Nasal Spray: First Needle-Free Anaphylaxis Treatment in U.K.
ARS Pharmaceuticals has secured UK approval for Eurneffy, its needle-free adrenaline nasal spray for anaphylaxis in adults and children...
Connect Biopharma at BTIG Virtual Biotech Conference
Connect Biopharma, a clinical-stage company focused on inflammatory diseases, is set to present at the BTIG Virtual Biotechnology Conference....
Kraig Biocraft Labs Expands Recombinant Spider Silk Output
Kraig Biocraft Laboratories is poised to significantly expand its recombinant spider silk production through a three-year collaborative agreement with...
ICT01 Awarded FDA Orphan Drug Designation for AML Treatment
ImCheck Therapeutics’ lead candidate, ict01, has received FDA orphan drug designation for acute myeloid leukemia (AML). This regulatory win...
Sanofi Acquires Blueprint Medicines
Sanofi Bolsters Rare Disease Portfolio and Immunology Presence with Blueprint Medicines Acquisition Sanofi has finalized its acquisition of Blueprint...
Successful Commercial Launch of Ryoncil®
Mesoblast Announces First Revenue Figures for Ryoncil, Offering Early Glimpse of Commercial Trajectory Mesoblast has reported US$13.2 million in...
Hookipa Pharma Delists Stock
Hookipa Pharma’s planned delisting from Nasdaq and subsequent dissolution signal the final chapter in the company’s independent journey. Following...
EU Conditionally Approves Ezmekly® (Mirdametinib) for NF1-PN Treatment
Merck’s Springworks Therapeutics secures landmark approval from the European Commission for Ezmekly (mirdametinib) for treating symptomatic, inoperable plexiform neurofibromas...
EZMEKLY® (Mirdametinib) Approved for NF1-PN by EU
The European Commission has granted conditional marketing authorization to Springworks Therapeutics’ Ezmekly (mirdametinib) for treating symptomatic, inoperable plexiform neurofibromas...